Recently, the “Private Seminar on Full-Chain Compliance Implementation for Finance, Taxation, Legal Affairs, and Operations in State-Owned and Central Enterprises in the Pharmaceutical Industry,” jointly organized by Gaodun Consulting, China Tax Consulting Group, and Yaoyi Cloud Technology, among others, was held at the International Business Lounge of the China World Trade Center Samsung Tower in Beijing. The theme of the event was “Navigating the 2026 Pharmaceutical Regulations: Addressing Pain Points, Clarifying Boundaries, and Mastering Practical Applications.” Attorney Weng Xiaoping, a senior partner at King&Capital Law Firm, was invited as a keynote speaker. He delivered a professional presentation on the latest “Judicial Interpretation (II) on Embezzlement and Bribery” and anti-corruption risk management in the pharmaceutical sector, and engaged in in-depth dialogue with several experts during the roundtable discussion.
This event brought together experts from the fields of taxation, law, and pharmaceutical practice. It focused on pain points in finance, taxation, legal affairs, and pharmaceutical operations—such as “upgraded audits under Phase IV of the Golden Tax Project,” “ “New Regulations on High-Tech and High-Value Cases Lowering the Threshold for Criminal Liability,” and “Strict Control of Compliance Baselines for Academic Promotion,” providing pharmaceutical companies and industry professionals with comprehensive compliance guidance ranging from policy interpretation to operational implementation.
During the legal session, Attorney Weng Xiaoping delivered a presentation titled “Interpretation of the New Provisions in the ‘Judicial Interpretation on Embezzlement and Bribery (II)’— —Managing Commercial Bribery and Industry Anti-Corruption Risks Under the New Pharmaceutical Regulations,” systematically outlined the core points of the “Two Highs” judicial interpretation. Drawing on typical scenarios such as pharmaceutical marketing and academic promotion, he vividly analyzed the red lines for commercial bribery in the pharmaceutical industry through real-life cases and proposed practical risk mitigation and compliance remediation strategies. Attorney Weng Xiaoping pointed out that, with the new regulations lowering the threshold for criminal liability, pharmaceutical companies urgently need to embed criminal compliance into their entire business process and build a defense mechanism that deeply integrates “business operations and risk control.”
During the subsequent roundtable discussion, Attorney Weng Xiaoping joined experts from the tax and pharmaceutical sectors—including Song Ning and Wang Wei—to focus on industry hot topics and discuss practical compliance challenges in the pharmaceutical sector. Their professional insights and practical experience were highly recognized by attendees.
This exclusive forum directly addressed the new regulatory landscape characterized by the deepening anti-corruption efforts in the pharmaceutical industry and the implementation of the new regulations on high-tech and high-growth enterprises. It established a practical platform for cross-disciplinary dialogue among finance, taxation, legal affairs, and business operations, providing effective guidance to state-owned and centrally administered pharmaceutical enterprises in overcoming obstacles to end-to-end compliance. Attorney Weng Xiaoping combines the theoretical foundation of a Ph.D. in criminal law with extensive frontline defense experience in major and complex cases. He has long specialized in the fields of occupational crimes, commercial bribery, and corporate compliance, excelling at translating legal provisions into actionable business safeguards. His insights, which blend a macro-policy perspective with rich practical experience, directly address corporate pain points, fully demonstrating the professional depth and practical capabilities of King&Capital Law Firm in the field of criminal compliance.
King&Capital Law Firm will continue to leverage its professional strengths in criminal defense and corporate compliance to provide robust support for enterprises in mitigating legal risks and ensuring compliant operations.
